LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

LeMaitre Vascular reports solid Q4 performance and eyes growth

LeMaitre Vascular's Q4 2022 performance showed growth in sales and income, with strong guidance for 2023.
Despite challenges with gross margin and product line issues, the company is well-positioned for future growth.
Opportunities lie in M&A, sales force expansion, and improving operational efficiency.
Strategic investments have bolstered the company's ability to meet demand and regulatory requirements.

LeMaitre Vascular reports robust Q1 sales and eyes Asia expansion

LeMaitre Vascular delivered strong sales and operating income in Q1 2023, driven by pricing strategies and market expansion efforts.
While facing challenges like rising expenses and competitor risks, the company aims to maintain profitability and drive growth through strategic initiatives.
Opportunities in Asia Pacific expansion and the Aziyo distribution agreement offer avenues for revenue growth and margin improvement.
Overall, LeMaitre's focus on maintaining margins, exploring new markets, and product innovation positions it for continued success in 2023.

LeMaitre Vascular reports robust Q2 sales growth and eyes international expansion

LeMaitre Vascular's Q2 performance reflects strong sales growth, pricing power, and operational efficiency, positioning the company for future success.
While facing margin challenges, the company's diversified product portfolio, international expansion plans, and solid cash position present growth opportunities.
Strategic focus on addressing challenges, optimizing operations, and capitalizing on growth opportunities will be crucial for sustained success and market leadership.

LeMaitre Vascular excels in Q3, eyes growth opportunities ahead

LeMaitre Vascular's Q3 performance was strong, with growth in sales and margins.
The company faces challenges in international markets and sales and marketing dynamics.
Opportunities lie in pricing strategies, product focus, and upcoming product filings.
Overall, LeMaitre Vascular is well-positioned for growth and strategic acquisitions.

LeMaitre Vascular posts strong Q4 results, eyes global expansion opportunities

LeMaitre Vascular's strong performance in Q4 2023 showcases robust sales growth and margin improvement.
While facing challenges such as ongoing impacts from the pandemic and tax rate assumptions, the company is well-positioned for growth.
Strategic initiatives like sales force expansion, APAC expansion, and M&A activities align with opportunities for market penetration and revenue growth.
Guidance for 2024 indicates a focus on operational efficiency and growth strategies to drive continued success.

LeMaitre Vascular excels in Q1 2024, eyes European expansion

Overall, LeMaitre Vascular's Q1 performance showcases strong financial growth, operational improvements, and strategic positioning for future success. The company's focus on expanding its market presence and product approvals sets a positive outlook for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LeMaitre Vascular's operating fundamentals and balance sheet suggest it's a buy, depending on your objectives.

Is This Under-the-Radar Medical Device Company a Post-Earnings Buy?

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2021 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 17.65% and -0.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Beats Q2 Earnings Estimates

BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2021 results, announced an $0.11/share quarterly dividend and provided guidance.

LeMaitre Q2 2021 Financial Results

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "

BURLINGTON, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2021 financial results on Thursday, July 29, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Second Quarter 2021 Earnings Results on July 29, 2021

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LeMaitre Vascular (LMAT) to Report Q2 Results: Wall Street Expects Earnings Growth

LeMaitre Vascular Inc (NASDAQ: LMAT) has announced preliminary Q2 2021 results and sees net sales of $40.7 million compared to an estimated $37.9 million, up 64%Y/Y on a reported basis and +35% organically. It expects gross margin in the range of 65.5% to 66.1%, -2.7% at the midpoint vs.

LeMaitre Vascular Sees Better Than Expected Q2 Sales, Raises $55M Via Equity At 9% Discount

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $54.50 per share. Gross proceeds to LeMaitre from the offering are expected to be approximately $54.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by LeMaitre. The offering is expected to close on or about July 16, 2021, subject to customary closing conditions. LeMaitre has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 150,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

LeMaitre Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by LeMaitre. In addition, LeMaitre intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

LeMaitre Vascular Announces Proposed Public Offering of Common Stock

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced preliminary unaudited results for the quarter ended June 30, 2021.

LeMaitre Provides Q2 2021 Update

Did LeMaitre Vascular jeopardize its payout with its recent 16% dividend lift?

Should Investors Consider This Expanding Healthcare Business After Its Massive Dividend Hike?

BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on Thursday, June 10, 2021, at 5:30 PM ET.

LeMaitre to Present at the Goldman Sachs Virtual Global Healthcare Conference

BURLINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today announced that it received CE marks under the European Medical Devices Directive (93/42/EC as amended by 2007/47/EC) for the following five products. Marks for the five products had previously lapsed due to a change in notified bodies.

LeMaitre Regains Five CE Marks

BURLINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 PM EDT.

LeMaitre to Present at the Jefferies Virtual Healthcare Conference

LeMaitre Vascular continues to present as a compelling investment case, with the economic pillars for long-term growth. Management expanded the balance sheet in FY2019, and have since put it to effective use in FY2020.

LeMaitre Vascular: Balance Sheet Expansion Adds ~$2 Per Share Value To Date

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

LeMaitre Vascular (LMAT) Recently Broke Out Above the 20-Day Moving Average

LeMaitre Vascular's (LMAT) CEO George LeMaitre on Q1 2021 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and 0.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Matches Q1 Earnings Estimates

Shares of LeMaitre Vascular (NASDAQ:LMAT) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 75.00% over the past year to $0.28, which beat the estimate of $0.27.

Recap: LeMaitre Vascular Q1 Earnings

Bull Of The Day: LeMatire Vascular (LMAT)

LeMaitre Vascular (LMAT) Earnings Expected to Grow: Should You Buy?

BURLINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2021 financial results on Thursday, April 29, 2021, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce First Quarter 2021 Earnings Results on April 29, 2021

Cantel Medical

Hill-Rom Hlds

Masimo

Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.

4 Critical Care Device Stocks to Deflect the COVID-19 Curveball

Abbott Labs

Hologic

IDEXX Laboratories

Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.

News for LeMaitre Vascular Stock (LMAT)